NEW YORK – Zephyr AI this week said it acquired Aster Insights, a provider of scientific and clinical intelligence, to support partnered personalized cancer medicine programs and improve patients' outcomes.

纽约——Zephyr AI本周表示，已收购科学与临床情报提供商Aster Insights，以支持合作的个性化癌症医学项目并改善患者的治疗效果。

Zephyr leverages real-world data and multimodal machine learning to inform clinical decision-making and advance drug discovery and development. The McClean, Virginia-based firm operates an artificial intelligence-driven platform and has significant genomic, exosomic, biopsy, and transcriptomic data assets.

Zephyr利用真实世界的数据和多模态机器学习来指导临床决策，并推动药物的发现与开发。这家位于弗吉尼亚州麦克莱恩的公司运营着一个由人工智能驱动的平台，并拥有大量的基因组、外体组、活检和转录组数据资产。

.

。

With the acquisition of Aster, Zephyr gains access to a longitudinal dataset from more than 400,000 patients who have given lifetime consent within a study conducted by a consortium of 17 US cancer centers, called the Oncology Research Information Exchange Network. Zephyr's own data resources combined with Aster's will enable it to expedite drug development, optimize patient stratification, design smarter clinical trials, and improve cancer care delivery..

通过收购Aster，Zephyr获得了来自40多万名患者的纵向数据集，这些患者在一个由17家美国癌症中心组成的联盟进行的研究中给予了终生同意，该联盟名为肿瘤学研究信息交换网络。Zephyr自身的数据资源与Aster的相结合，将能够加速药物开发、优化患者分层、设计更智能的临床试验，并改善癌症治疗的提供。

Zephyr previously partnered with M2Gen

Zephyr之前与M2Gen合作过

in 2023

2023年

to obtain a real-world longitudinal dataset from 350,000 cancer patients. In 2024, Zephyr

从350,000名癌症患者中获取一个真实世界的纵向数据集。2024年，Zephyr

raised $111 million

筹集了1.11亿美元

in Series A financing to develop an

在A轮融资中开发一项新技术

AI-driven technology platform

人工智能驱动的技术平台

that aggregates and analyzes datasets for drug discovery and patient care.

用于药物发现和患者护理的数据集聚合与分析。

Aster and Zephyr have begun integrating their capabilities and have biomarker discovery, clinical trial optimization, and AI-enabled companion diagnostics development initiatives underway.

Aster和Zephyr已经开始整合他们的能力，并正在进行生物标志物发现、临床试验优化和人工智能辅助诊断开发等项目。

'This acquisition deepens Zephyr's data advantage and reinforces our commitment to using AI and real-world evidence to unlock more effective, personalized therapies,' Zephyr CEO Allen Chao said in a statement. 'We believe the combination of Zephyr's platform and Aster Insights' unparalleled data access positions us to deliver differentiated insights to our life science partners and, ultimately, better patient outcomes.'.

Zephyr首席执行官赵艾伦在一份声明中表示：“此次收购加深了Zephyr的数据优势，并强化了我们利用人工智能和真实世界证据来开发更有效、更个性化疗法的承诺。” “我们认为，Zephyr平台与Aster Insights无与伦比的数据访问能力相结合，将使我们能够为生命科学合作伙伴提供差异化的洞察，并最终带来更好的患者治疗效果。”

Zephyr also announced this week that it has appointed Chao, founder of Watson Pharmaceuticals, as its CEO. From 2022 to 2024, David Morgan, now CEO of Certified Group, was Zephyr's CEO.

Zephyr 本周还宣布，已任命华生制药创始人赵超为 CEO。2022 年至 2024 年期间，Certified Group 现任首席执行官 David Morgan 曾担任 Zephyr 的 CEO。